drugset / Trial / NCT07684157
A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.
Timeline
- Start
- 2026-07-29
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JAB-8263 | Small molecule | — | Oral |